Chemotherapy is a type of cancer treatment which consists of the use of one or more chemotherapeutic agents including anti-cancer drugs. The treatment mainly prevents the cancer cells division and growth of cancer cells by killing the dividing cells. Moreover, it is used in the treatment of different types of cancer such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others. The chemotherapy drugs can be managed directly into the bloodstream or can be targeted to exact cancer sites. However, this treatment also includes several side effects such as nausea & vomiting, alopecia, hair loss, fatigue, hearing impairment, mucositis, loss of appetite, and many more.
According to the America Cancer Society, lung cancer is estimated to be the second most common cancer in both male and female. In males, prostate cancer is more common, while in female breast cancer is more common. Additionally, about 14% of all new cancers are lung cancers. Moreover, the American Cancer Society’s evaluations for lung cancer in the United States for 2018 are:
• About 234,030 new cases of lung cancer (121,680 in men and 112,350 in women)
• About 154,050 deaths occur from lung cancer (83,550 in men and 70,500 in women)
According to the Leukemia and Lymphoma Society, around every 3 minutes, one person in the United States (US) is diagnosed with a blood cancer. Moreover, an estimated combined total of 172,910 people in the US were diagnosed with leukemia, lymphoma or myeloma in 2017.
Factors Influencing the Market Scenario:
The market is driven by several factors including growing prevalence of different types of cancers such as lung cancer, sarcoma, lymphoma, breast cancer, myeloma, and others. According to the breastcancer.org, in 2018, it is estimated that about 266,120 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 63,960 new cases of non-invasive breast cancer. Additionally, it is estimated that about 2,550 new cases of invasive breast cancer are predicted to be diagnosed in men in 2018. A man’s lifetime risk of breast cancer is about 1 in 1,000.
Moreover, the technological advancements and rising emphasis on research and development in the field of oncology may propel the growth of the market.
However, the huge cost of treatment and poor reimbursement policies in the developing regions are some of the restraining factors of the market.
Geographically, the market is split into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA). The North American market is mainly driven by the growing number of market players engaged in manufacturing the chemotherapy drugs, the rising patient population, and growing healthcare expenditure. Additionally, available healthcare facilities and use of advanced technologies in cancer research and treat also drive the market in this region.
Europe also contributes to the growth of the market owing to rising government support for research and development and growing pharmaceutical companies engaged in research for the various types of cancer. Moreover, Asia Pacific is predicted to be the fastest growing region due to the growing demand for chemotherapy drugs and the accessibility of well-qualified and capable healthcare professionals such as oncologists and also due to the fastest growth of healthcare sector. The market is also growing in the Middle East & Africa due to growing awareness about various types of cancer, their diagnosis, and different availability of treatment options.
The global chemotherapy market comprises of various major players including Sanofi, Novartis, Pfizer Inc., Eli Lilly & Company, ImClone Systems Inc., GlaxoSmithKline, AstraZeneca, Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceuticals Industries, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Chemo Espana SL, CELGENE CORPORATION, Amgen Inc, Bayer AG, Takeda Pharmaceutical Company Limited, and others.
For instance, in July 2017, TESARO, Inc. and Takeda Pharmaceutical Company Limited announced an exclusive licensing agreement for the commercialization and clinical development of novel cancer therapy ‘niraparib’, in Japan.
For instance, in May 2018, it has been announced in Bhopal that cancer patients will get free chemotherapy at district hospitals. This was done under the Cancer Care Programme.
Additionally, in May 2018, Tech giant Microsoft announced a partnership with the Fred Hutchinson Cancer Research Centre to tackle chemotherapy side effects using new AI tech.
Chemotherapy Market Segmentation
• Alkylating Agents
o Mustard Gas Derivatives
o Alkyl Sulfonates
• Anti-Tumor Antibiotics
• Topoisomerase Inhibitors
o Topoisomerase I Inhibitors
o Topoisomerase Ii Inhibitors
• Mitotic Inhibitors
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
By Route of Drug Administration:
• Research Institutes
o North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA